Weight loss often becomes steadier once you reach higher therapeutic doses
This looks to be a pretty common tactic as a similar situation occurred last year with Eli Lillys tirzepatide, manufactured under the names Mounjaro for the treatment of diabetes and Zepbound for the treatment of obesity
See our detailed breakdown in GHK-Cu vs NAD+: A Clinical Comparison of Two Longevity Peptide Therapies
The benefits go beyond the number on the scale
Fatigue may occur because the body is adjusting to treatment, but it may also reflect under-eating, low protein intake, dehydration, electrolyte changes, rapid weight loss, poor sleep, constipation, low blood sugar, low blood pressure, or another medical issue
Out of 2139 patients with HFrEF and type 2 diabetes mellitus, 1211 (57%) were older than 65 years